Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783545 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of VLX-1005 in Healthy Subjects
A Phase 1 study, sponsored by Veralox Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT04783545: Completed Phase 1 study, sponsored by Veralox Therapeutics.
NCT04783545 is a Phase 1 study that has completed, run by Veralox Therapeutics. The registered enrollment target is 96 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04783545, a Phase 1 study, has completed, sponsored by Veralox Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration.
Interventions
- DRUG Placebo
- DRUG VLX-1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2022-01-11 |
| Phase | Phase 1 |
What the finished NCT04783545 record still lists
NCT04783545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04783545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04783545 about?
NCT04783545 is a clinical study titled "Phase I Study of VLX-1005 in Healthy Subjects". The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following ...
What is the current status of trial NCT04783545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2021-03-24. Estimated completion is 2022-01-11.
What interventions are being tested in trial NCT04783545?
The interventions under investigation include: Placebo (DRUG), VLX-1005 (DRUG).
Who is sponsoring clinical trial NCT04783545?
This trial is sponsored by Veralox Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04783545's enrollment target sits among peer trials
96 600th of 2000 higher than 1,391 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI